Pejvack Motlagh *
With over 20 years of experience in the pharmaceutical and biotechnology industry, Dr. MOTLAGH brings extensive expertise in drug development strategy across multiple therapeutic areas. His leadership will be instrumental in shaping GENFIT’s clinical development programs and advancing its pipeline. Prior to joining GENFIT, Dr. MOTLAGH served as CMO at Egle Therapeutics, a company focused on therapies targeting regulatory T cells for oncology and autoimmune diseases. He also held the role of CMO at Mablink Biosciences, a biotechnology company specializing in next-generation antibody-drug conjugates (ADCs). Earlier in his career, Dr. MOTLAGH contributed to the success of several large pharmaceutical organizations, playing a key role in advancing compounds from early phase clinical development up to commercialization.